Testing a new combination therapy for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, RZ-001, combined with valganciclovir, atezolizumab, and bevacizumab for people with hepatocellular carcinoma (a type of liver cancer). The goal is to see if this combination is safe and works better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (18 years or older).
- You must have been diagnosed with hepatocellular carcinoma (liver cancer) at a specific stage (B or C).
- Your tumor must have a protein called hTERT, which will be checked during screening.
- You must be in fairly good health (ECOG score of 0 or 1) and have a Child-Pugh score of A, meaning your liver is working well.
- You must have a life expectancy of at least 3 months.
- You cannot have moderate or severe fluid buildup in your belly (ascites), a history of hepatic encephalopathy (liver-related brain issues), or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines three medications—an immunotherapy (atezolizumab), a drug that blocks blood vessel growth (bevacizumab), and one that reduces inflammation (tocilizumab)—to see if they work together against advanced liver cancer. The goal is to slow cancer growth and possibly shrink the tumor.
This study looks at how well a combination of two drugs (atezolizumab and bevacizumab) works for people with liver cancer in real life, outside of a clinical trial. It will help doctors understand the treatment's benefits and risks based on patient records.
This trial tests a new way to find and treat liver cancer that cannot be removed by surgery. First, a special dye (RYZ811) is used to see if your cancer cells have a marker called GPC3. If they do, you may receive a targeted radiation treatment (RYZ801) that seeks out those cells. This trial is for people whose liver cancer has grown despite receiving at least one prior therapy.
This trial tests a new drug called SH006 combined with another treatment against a standard drug (regorafenib) for advanced liver cancer. It is for people whose cancer has stopped responding to immunotherapy, and the goal is to see if it helps them live longer or shrinks the tumor.
This trial tests a new drug combination (ZG005 plus bevacizumab) against a standard one (sintilimab plus bevacizumab) as the first treatment for advanced liver cancer that cannot be removed by surgery. The goal is to see if the new combination works better at shrinking tumors or delaying progression.
This trial tests a new drug combination (rilvegostomig plus bevacizumab, with or without tremelimumab) as a first treatment for people with advanced liver cancer (HCC) that cannot be removed by surgery or treated with local therapies. It aims to see if these combinations help shrink tumors or slow disease progression.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.